Alexandre O. Gérard

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

Alexandre O. Gérard, Serena Romani, Audrey Fresse et al. · Therapies · 2020 · 144 citations · Full text

Drug Safety, Drug Interactions, Cardiovascular Toxicity +12

Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients

Filippo Massa, Marion Crémoni, Alexandre O. Gérard et al. · EBioMedicine · 2021 · 80 citations · Full text

Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

Alexandre O. Gérard, Audrey Laurain, Audrey Fresse et al. · Clinical Pharmacology & Therapeutics · 2020 · 67 citations

World Health Organization, Pharmacotherapy, Logistic Analysis +23

Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses

Marion Crémoni, Vesna Brglez, Sandra Pérez et al. · Frontiers in Immunology · 2020 · 56 citations · Full text

Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database

Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen et al. · The Journal of Headache and Pain · 2022 · 39 citations · Full text